Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia

Current Opinion in Investigational Drugs

Volumn 3, Issue 8, 2002, Pages 1171-1180

  Jeske, Walter P ^a   Walenga, Jeanine M ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Anticoagulants; Antithrombotics; Direct anti IIa; Heparin; Side effects; Thrombocytopenia; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACOVA; ANCROD; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DANAPAROID; DEXTRAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; ILOPROST; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; ORGANAN; THROMBIN INHIBITOR; TIROFIBAN; UROKINASE; WARFARIN;

AMPUTATION; ANAPHYLAXIS; ANTICOAGULATION; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DEATH; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG USE; HEART SURGERY; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; LOW DRUG DOSE; PATHOPHYSIOLOGY; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE THROMBOSIS; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; SIDE EFFECT; SKIN NECROSIS; TACHYPHYLAXIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPLASTIN TIME; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; CHONDROITIN SULFATES; DERMATAN SULFATE; DRUG COMBINATIONS; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARITIN SULFATE; HIRUDINS; HUMANS; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 0036707339     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecular-weight heparin, mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest (2001) 119(1 Suppl):64S-94S.
2. Lewis BE, Walenga JM, Wallis DE: Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Haemost (1997) 23(2):197-202.
3. Messmore HL, Upadhyay G, Farid S, Parachuri R, Wehrmacher W, Godwin J: Heparin-induced thrombocytopenia and thrombosis in cardiovascular surgery. In: New Anticoagulants for the Cardiovascular Patient. Pifarré R (Ed), Hanley & Belfus Inc, PA, USA (1993):83-94.
4. Walenga JM, Lewis BE, Hoppensteadt DA, Fareed J, Bakhos M: Management of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Clin Appl Thromb Haemost (1997) 3 (Suppl 1):S53-S63.
5. Warkentin TE, Kelton JG: Temporal aspects of heparin-induced thrombocytopenia. New Engl J Med (2001) 344(17):1286-1292.
6. Warkentin TE, Kelton JG: Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med (2001) 135(7):502-506.
7. Walenga JM, Jeske WP, Wood JJ, Ahmad S, Lewis BE, Bakhos M: Laboratory tests for heparin-induced thrombocytopenia: A multicenter study. Semin Hematol (1999) 36(Suppl 1):22-28.
8. Walenga JM, Jeske WP, Fasanella AR, Wood JJ, Ahmad S, Bakhos M: Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost (1999) 5(Suppl 1):S21-S27.
9. Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG: Sera from patients with heparin-induced thrombocytopenia generate platelet derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin induced thrombocytopenia. Blood (1994) 84(11):3691-3699.
10. Warkentin TE, Kelton JG: A 14-year study of heparin-induced thrombocytopenia. Am J Med (1996) 101(5):502-507. The authors document the high occurrence of venous thrombosis in patients with HIT and the high 30-day risk of developing thrombosis in patients initially recognized with isolated thrombocytopenia.
11. Greinacher A, Eckhardt T, Mussman J, Mueller-Eckhardt C: Pregnancy complicated by heparin associated thrombocytopenia: Management by a prospective in vitro selected heparinoid (ORG 10172). Thromb Res (1993) 71(2):123-126.
12. Stewart MW, Etches WS, Boshkov LK, Gordon PA: Heparin-induced thrombocytopenia: An improved method of detection based on lumi-aggregometry. Br J Haematol (1995) 91(1):173-177.
13. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarré R, Moran JF: Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med (1999) 106(6):629-635. Retrospective study of 113 patients with HIT, demonstrating that early cessation of heparin did not reduce the morbidity associated with HIT.
14. Moberg PQ, Geary VM, Sheikh FM: Heparin-induced thrombocytopenia: A possible complication of heparin-coated pulmonary artery catheters. J Cardiothoracic Anesth (1990) 4(2):226-228.
15. Weismann RE, Tobin RW: Arterial embolism occurring with systemic heparin therapy. Arch Surg (1958) 76:219-227.
16. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost (1992) 68(1):95-96.
17. Aster RH: Heparin-induced thrombocytopenia and thrombosis. N Engl J Med (1995) 332(20):1374-1376.
18. Brandt JT, Isenhart CE, Osborne JM, Ahmed A, Anderson CL: On the role platelet FcγRIIA phenotype in heparin-induced thrombocytopenia. Thromb Haemost (1995) 74(6):1564-1572.
19. Cines DB, Tomaski A, Tannenbaum S: Immune endothelial-cell injury in heparin associated thrombocytopenia. N Engl J Med (1987) 316(1):581-589.
20. Greinacher A, Michels I, Liebenhoff U, Presek P, Mueller-Eckhardt C: Heparin-associated thrombocytopenia: Immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol (1993) 84(4):711-716.
21. Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C: Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost (1994) 71(2):247-251.
22. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood (1994) 83(11):3232-3239.
23. Visentin GP, Ford SE, Scott JP, Aster RH: Antibodies from patients with heparin-induced thrombocytopenai/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest (1994) 93(1):81-88.
24. Jeske WP, Walenga JM, Szatkowski E, Ero M, Herbert JM, Haas S, Bakhos M. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res (1997) 88(3):271-281.
25. Walenga MJ, Michal K, Hoppensteadt D, Wood JJ, Bick RL, Robinson JA: Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost (1999) 5(Suppl 1):S76-S84.
26. Herbert JM, Savi P, Jeske WP, Walenga JM: Effect of SR121566A, a potent GP IIb/IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost (1998) 80(2):326-331.
27. Chong BH: Heparin-induced thrombocytopenia. Br J Haematol (1995) 89(3):431-439.
28. Walenga JM, Koza MJ, Lewis BE, Pifarré R: Relative heparin induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost (1996) 2(Suppl 1):S21.
29. Newman PM, Chong BH: Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood (2000) 96(1):182-187.
30. Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y: Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood (2001) 97(10):3300-3302.
31. Hughes M, Hayward CP, Warkentin TE, Horsewood P, Chorneyko KA, Kelton JG: Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood (2000) 96(1):188-194.
32. Jeske WP, Schlenker R, Bakhos M, Walenga JM: Are leukocytes important for platelet activation in heparin-induced thrombocytopenia? Ann Hematol (2000) 79(Suppl 2):A46.
33. Jeske WP, Vasaiwala S, Schlenker R, Wallis E, Walenga JM: Leukocyte activation in heparin-induced thrombocytopenia. Blood (2000) 96(11):Abs 3785.
34. Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, Walenga MJ, Amiral J, Eldor A: Anti-PF4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol (2002) 14(2):121-129.
35. Baugh MJ, Prechel M, Hoppensteadt D, Wallis E, Bick RL, Walenga JM: The role of CD40-ligand and anti-annexin V antibodies in the pathophysiology of the APS and HIT. Blood (2000) 96(11):1167.
36. Ahmad S, Walenga JM, Jeske WP, Cella G, Fareed J: Functional heterogeneity of antiheparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome. Clin Appl Thromb Hemost (1999) 5(Suppl 1):S32-S37.
37. Ahmad S, Walenga JM, Jeske WP, Hoppensteadt DA, Khan E, Cella G, Messmore HL: Lack of thrombocytopenic responses after low molecular weight heparin usage is due to the generation of non-functional anti-heparin-platelet factor 4 antibodies. Blood (1999) 94(10):Abs 2270.
38. Mattioli AV, Bonetti L, Sternieri S, Mattioli G: Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: Prevalence of thrombosis in a 1 year follow-up. Ital Heart J (2000) 1(1):39-42. This study shows an increase in thrombotic events during a one-year follow-up in patients with anti-heparin/PF4 antibodies compared to those without antibodies, despite no evidence of thrombocytopenia.
39. Amiral J, Pouplard C, Vissac AM, Walenga JM, Jeske W, Gruel Y: Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: Biological characteristics and effects on platelet activation. Br J Haematol (2000) 109(2):336-341.
40. Pouplard CA, Amiral J, Vissac AM, Walenga JM, Jeske WP, Gruel YJ: Affinity purification of different heparin-dependent antibodies to platelet factor 4 developed in HIT. Biological characteristics and effects on platelet activation. Blood (1999) 94(10):Abs 54.
41. Carlsson LE, Santoso S, Baurichter G, Kroll H, Papenberg S, Eichler P, Westerdaal NA, Kiefel V, Van De Winkel JG, Greinacher A: Heparin-induced thrombocytopenia: New insights into the impact of the FcγRIIa-R-H131 polymorphism. Blood (1998) 92(5):1526-1531.
42. Kappa JR, Fisher CA, Berkowitz HD, Cottrell ED, Addonizio VP: Heparin-induced platelet activation in sixteen surgical patients: Diagnosis and management. J Vasc Surg (1987) 5(1):101-109.
43. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 332(20):1330-1335.
44. Ahmad S, Walenga JM, Jeske WP, Hoppensteadt DA, Bakhos M: Molecular weight and charge dependence of heparin on the pathogenic responses of anti-heparin platelet factor 4 antibodies. Thromb Haemost (2001) 86(Suppl):P2729.
45. Greinacher A, Feigl M, Mueller-Eckhardt C: Crossreactivity studies between sera of patients with heparin associated thrombocytopenia and a new low molecular weight heparin, reviparin. Thromb Haemost (1994) 72(4):644-645.
46. Altes A, Martino R, Gari M, Camara ML, Garin R, Casas JI, Fontcuberta J: Heparin-induced thrombocytopenia and heart operation: Management with tedelparin. Ann Thorac Surg (1995) 59(2):508-509.
47. Leroy J, Leclerc MH, Delahousse B, Guerois C, Foloppe P, Gruel Y, Toulemonde F: Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin Thromb Hemost (1985) 11(3):326-329.
48. Robitaille D, Leclerc JR, Laberge R, Sahab P, Atkinson S, Cartier R: Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg (1992) 103(3):597-599.
49. Roussi JH, Houbouyan LL, Goguel AF: Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet (1984) 1(8387):1183.
50. Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC. Thrombocytopenia associated with low-molecular-weight heparin. Lancet (1991) 337(8754):1425-1426.
51. Gouault-Heilmann M, Payen D, Contant G, Intrator L, Huet Y, Schaeffer A. Thrombocytopenia related to synthetic heparin analogue therapy. Thromb Haemost (1985) 54(2):557.
52. Wallis DE, Quintos R, Whermacher W, Messmore H: Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest (1999) 116(5):1333-1338.
53. Walenga JM, Fasanella AR, Iqbal O, Hoppensteadt DA, Ahmad S, Wallis DE, Bakhos M: Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost (1999) 25(Suppl 1):61-66.
54. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK: Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost (2001) 85(3):435-440.
55. Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP: The interventional normalization ratio during concurrent warfarin and argatroban anticoagulation: Differential contributions of each agent and effects of the choice of the thromboplastin used. Clin Chem (1999) 45(13):409-412.
56. Lewis BE, Leya FS, Wallis D, Grassman E: Failure of ancrod in the treatment of heparin-induced arterial thrombosis. Can J Cardiol (1994) 10(5):559.
57. Chamberlin JR, Lewis B, Leya F, Wallis D, Messmore H, Hoppensteadt D, Walenga JM, Moran S, Fareed J, McKiernan T: Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol (1995) 11(6):511-514.
58. Walenga JM, Lewis BE, Jeske WP, Leya F, Wallis DE, Bakhos M, Fareed J: Combined thrombin and platelet inhibition treatment for HIT patients. Hämostaseologie (1999) 19:128-133. This paper describes the use of a combination of GPIIb/IIIa and direct thrombin inhibitors for the treatment of acute thrombosis in patients with HIT.
59. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK et al: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation (2001) 103(14):1838-1843. Argatroban reduces all-cause death, all-cause amputation and new thrombosis in patients with HIT.
60. Lewis BE, Ferguson JJ, Grassman ED, Fareed J, Walenga JM, Joffrion JL, Wrona L, Johnson SA, Schwarz RP, McKiernan T: Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invasive Cardiol (1996) 8(9):410-417.
61. Lewis BE, Iqbal O, Hoppensteadt D, Ahsan A, Ahmad S, Messmore HL, Schwarz RP, Walenga JM: Clinical pharmacokinetic and pharmacodynamic studies on argatroban to optimize the anticoagulant dosage in interventional cardiovascular procedures. Thromb Haemost (1997) (Suppl):492.
62. Lewis BE, Rangel Y, Fareed J: The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome: A case report. Angiology (1998) 49(1):61-67.
63. Lewis BE, Cohen M, Moses J, Matthai W, for the ARG-216/310/311 investigators: Argatroban anticoagulation during initial and repeat percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Am J Cardiol (2000) 86(Suppl 8A):141.
64. Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Pötzsch B: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation (1999) 99(1):73-80. Clinical benefit of recombinant hirudin treatment in HIT patients is described.
65. Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, Eichler P, Volpel H, Pötzsch B, Luz M: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation (1999) 100(6):587-593.
66. Pötzsch B, Klovekorn WP, Madlener K: Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med (2000) 343(7):515.
67. Koster A, Loebe M, Mertzlufft F, Kuppe H, Hetzer R: Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GPIIb/IIIa inhibitor tirofiban as anticoagulant. Ann Thorac Surg (2000) 70(6):2160-2161.
68. Kappa JR, Fisher CA, Todd B, Stenach N, Bell P, Campbell F, Ellison N, Addonizio VP: Intraoperative management of patients with heparin-induced thrombocytopenia. Ann Thorac Surg (1990) 49(5):714-722.
69. Fabrizio MC: Use of the escarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Tech (2001) 33(2):117-125.
70. Riess FC, Kormann J, Poetzsch B: Recombinant hirudin as anticoagulant during cardiopulmonary bypass. Anesthesiology (2000) 93(6):1551-1552.
71. Shah AC, Genoni M, Niederhauser U, Maloigne M, Turina M: R-hirudin (lepirudin, refludan) as an alternative anticoagulant in heparin-induced thrombocytopenia during cardiopulmonary bypass connection. Schweiz Med Wochenschr (2000) 130(23):896-899.
72. Rubens FD, Sabloff M, Wells PS, Bourke M: Use of recombinant-hirudin in pulmonary thromboendarterectomy. Ann Thorac Surg (2000) 69(6):1942-1943.
73. Koster A, Loebe M, Hansen R, Bauer M, Mertzlufft F, Kuppe H, Hetzer R: A quick assay for monitoring hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: Adaptation of the ecarin clotting time to the ACT II device. J Thorac Cardiovasc Surg (2000) 119(6):1278-1283.
74. Longrois D, De Maistre E, Bischoff N, Dopff C, Meistelman C, Angioi M, Lecompte T: Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can J Anaesth (2000) 47(3):255-260.
75. Latham P, Revelis AF, Joshi GP, DiMaio JM, Jessen ME: Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology (2000) 92(1):263-266.
76. Koster A, Pasic M, Bauer M, Kuppe H, Hetzer R: Hirudin as anticoagulant for cardiopulmonary bypass: Importance of preoperative renal function. Ann Thorac Surg (2000) 69(1):37-41.
77. Koster A, Kuppe H, Hetzer R, Sodian R, Crystal GJ, Mertzlufft F: Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology (1998) 89(3):777-780.
78. Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN: Heparin-induced thrombocytopenia: Studies with a new low molecular weight heparinoid, Org 10172. Blood (1989) 73(6):1592-1596.
79. Haas S, Walenga JM, Jeske WP, Fareed J: Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors. Clin Appl Thromb Hemost (1999) 5(1):52-59.
80. Magnani HN: Heaprin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost (1993) 70(4):554-561.
81. Ortel TL, Gockerman JP, Califf RM, McCann RL, O'Connor CM, Metzler DM, Greenberg CS: Parenteral anticoagulation with the heparinoid Lomoparan (ORG 10172) in patients with heparin-induced thrombocytopenia and thrombosis. Thromb Haemost (1992) 67(3):292-296.
82. Cohen JI, Cooper MR, Greenberg CS: Streptokinases therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch Intern Med (1985) 145(9):1725-1726.
83. Fiessinger JN, Aiach M, Roncato M, Debure C, Gaux JC: Critical ischemia during heparin-induced thrombocytopenia. Treatment by intra-arterial streptokinase. Thromb Res (1984) 33(2):235-238.
84. Rao RC, Lewis BE, Johnson SA: Thrombolytic experience for treatment of thrombosis in patients with post-operative heparin-induced thrombocytopenia. Blood (1995) 86(10 Suppl 1):551a.
85. Haas S, Walenga JM, Jeske WP, Fareed J: Heparin-induced thrombocytopenia: The role of platelet activation and therapeutic implications. Semin Thromb Hemost (1999) 25(Suppl 1):67-75.